Why Provectus Biopharmaceuticals (PVCT) Stock Is Plunging Today

NEW YORK (TheStreet) -- Provectus Biopharmaceuticals  (PVCT) plunged Wednesday after the site amended its website homepage to call PV-10 an "investigational drug for cancer" after it had previously called it a "breakthrough cancer drug."

TheStreet's Adam Feuerstein posted an article with screenshots of the two homepage descriptions and he points out Provectus is supposed to get a response from the FDA this week about its request to grant PV-10 Breakthrough Therapy status for skin cancer. The company has said nothing thus far about the FDA's response.

Seeking Alpha also posted an extremely bearish article on Provectus on Wednesday.

Must Read: Provectus Disappears 'Breakthrough' Drug Claim on Web Site

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The stock was down 18.15% to $2.21 at 12:08 p.m.

PVCT Chart

PVCT data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

Airlines Rebuke Trump Policy of Separating Children

Airlines Rebuke Trump Policy of Separating Children

Dow Fluctuates, Nasdaq Strikes Record High

Dow Fluctuates, Nasdaq Strikes Record High

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists

Deutsche Bank Fined $205 Million Over Currency-Trading Violations

Deutsche Bank Fined $205 Million Over Currency-Trading Violations

Instagram Launches New Longform Video Platform

Instagram Launches New Longform Video Platform